A Luxembourg pilot combines a cancer registry, occupational health records and surveys: 77% of participants returned to work after breast cancer, especially younger women....
Across three independent cohorts, low PGR expression is linked to higher genomic risk and poorer prognosis, but the study does not assess treatment response....
A US economic model estimates that comprehensive sequencing directs more patients to targeted therapies with minimal budget impact compared with 50-gene panels....
An observational study in 102 patients reports a 57.4% pathological complete response with CT-P6 plus pertuzumab and chemotherapy, with no signs of immunogenicity....
An analysis of the plasmaMATCH trial shows that low circulating tumor DNA levels and their disappearance during treatment are linked to better responses....
A retrospective analysis of 8,825 patients from GEICAM studies places 10-year invasive disease-free survival at 73.8% for the intermediate-risk group....
The Global Burden of Disease 2023 estimates 2.30 million cases and 764,000 deaths in 2023, and forecasts a sharp rise by 2050 with wide inequalities between countries....
A qualitative study at Miguel Servet Hospital in Zaragoza identifies five themes that most shift emotions, especially side effects and waiting times....
Genomic analysis of the SOLAR-1 trial shows that patients with FGFR1 or FGFR2 alterations or low mutational burden gain more from alpelisib plus fulvestrant....
The Spanish PROCURE project, with 292 patients, finds that UGT1A1 genotypes do not explain the adverse effects of trastuzumab-deruxtecan in advanced breast cancer....
An analysis of the Spanish El Álamo IV registry shows that age, stage, histological grade and tumour subtype are linked to distinct relapse patterns....
The Spanish SOLTI-1303 PATRICIA trial shows the triplet improves progression-free survival versus standard care in HER2-positive luminal tumours....